Cell Therapeutics Inc (NASDAQ:CTIC) selling preferred stock


Dallas, Texas 09/18/2013 (Financialstrend) – Cell Therapeutics Inc (NASDAQ:CTIC), the biopharma company is selling 15,000 shares of Series-18 preferred stock directly to a Perceptive Advisors LLC affiliate and Quogue Capital LLC for gross-proceeds of $15M in a registered direct-offering.

After deducting all estimated offering-expenses, the net proceeds of the offering will amount to around $14.8 million.

The company added that each share of Series-18 preferred stock will have a $1,000/share stated-value. It will be convertible at the holder’s choice, at any time before the automatic-conversion of such shares in specific circumstances, into 15 million registered common-shares at a conversion-price of $1.00/share of common-stock.

Sale proceeds

Cell Therapeutics Inc (NASDAQ:CTIC)will use the net proceeds of this sale  to continue the pacritinib PhaseIII trials and to support  commercialization of PIXUVRI in Europe, Funding R&D, general corporate purposes, clinical and preclinical trials, the preparation and filing of NDA’s as well as general working capital.

Tuesday’s trading

In Tuesday’s trading session Cell Therapeutics Inc (NASDAQ:CTIC) stock rose by 10.48%. The opening price of the shares was $1.23 which climbed to an intraday high of $1.49 and dipped to close at $1.37. Approximately 5.96 million shares exchanged hands on Tuesday and the average-volume of shares traded over a 30 day period was 1.08 million. The company has a market cap of $157.24 million.

About the company

Cell Therapeutics Inc (NASDAQ:CTIC) is a bio-pharma company. It focuses on acquiring, developing and commercializing less-toxic methods to treat cancer. It is channelizing its efforts on various treatments that target different blood-related cancers where there is a vast unmet medical need. It primarily focuses on the commercialization of PIXUVRI in the EU. This is use for multiplie-relapsed or refractory-aggressive non-Hodgkin lymphoma and is also conducting a Phase-III clinical trial of the drug, pacritinib for myelofibrosis treatment.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.